Monopar to Present at the 34th Annual Roth Conference and Maxim’s 2022 Virtual Growth Conference
Monopar Therapeutics (Nasdaq: MNPR) announces that CEO Chandler Robinson will present at two upcoming conferences. The 34th Annual Roth Conference is scheduled for March 14, 2022, at 1:30 PM Pacific Time, at The Ritz Carlton in Laguna Niguel, California. The Maxim’s 2022 Virtual Growth Conference will take place on March 30, 2022, at 4:30 PM Eastern Time. Monopar focuses on therapeutics aimed at improving the lives of cancer patients, with a pipeline that includes Validive® and camsirubicin.
- None.
- None.
WILMETTE, Ill., March 08, 2022 (GLOBE NEWSWIRE) -- Monopar Therapeutics Inc. (Nasdaq: MNPR), a clinical-stage biopharmaceutical company focused on developing proprietary therapeutics designed to extend life or improve the quality of life for cancer patients, today announced that Chandler Robinson, MD, Monopar’s Chief Executive Officer, will present at the 34th Annual Roth Conference and Maxim’s 2022 Virtual Growth Conference.
Presentation Details:
34th Annual Roth Conference
https://www.roth.com/conferences/upcoming-conferences
Date: March 14, 2022
Time: 1:30pm Pacific Time
Location: The Ritz Carlton, Laguna Niguel located in Dana Point, California
Maxim’s 2022 Virtual Growth Conference
https://www.m-vest.com/home
Date: March 30, 2022
Time: 4:30pm Eastern Time
Location: https://m-vest.com/events/2022-virtual-growth-conference
About Monopar Therapeutics Inc.
Monopar Therapeutics is a clinical-stage biopharmaceutical company focused on developing proprietary therapeutics designed to extend life or improve the quality of life for cancer patients. Monopar's pipeline consists of Validive® for the prevention of chemoradiotherapy-induced severe oral mucositis in oropharyngeal cancer patients; camsirubicin for the treatment of advanced soft tissue sarcoma; a late-stage preclinical antibody, MNPR-101, for advanced cancers and severe COVID-19; and an early-stage camsirubicin analog, MNPR-202, for various cancers. For more information, visit: www.monopartx.com.
CONTACT:
Monopar Therapeutics Inc.
Investor Relations
Kim R. Tsuchimoto
Chief Financial Officer
kimtsu@monopartx.com
Follow Monopar on social media for updates:
Twitter: @MonoparTx LinkedIn: Monopar Therapeutics
FAQ
What is Monopar Therapeutics doing at the 34th Annual Roth Conference?
When is the Maxim’s 2022 Virtual Growth Conference?
What is the stock symbol for Monopar Therapeutics?
What is the focus of Monopar Therapeutics?